Objective: To explore the efficacy of vonoprazan fumarate in the treatment of laryngopharyngeal reflux disease（LPRD） evaluated by the Chinese version of the RSS-12 scale. Methods:A total of 100 LPRD patients treated in the otolaryngology-head and neck surgery outpatient clinic of our hospital were randomly divided into two groups（50 cases each）. The observation group was treated with vonoprazan fumarate（20 mg, once daily）, and the control group was treated with esomeprazole enteric-coated capsules（20 mg, twice daily） for 12 weeks. The selected observation indicators in this study included RSI, the Chinese version of RSS-12, and RFS scores before and after treatment. Results:Prior to treatment, there was no statistically significant difference in the Chinese version of RSS-12, RSI, and RFS between the two groups（P>0.05）. After 8 and 12 weeks of antacid treatment, both the Chinese version of RSS-12 and RSI significantly decreased in both group （P<0.05）. The changes in symptoms were particularly noticeable between 0-8 weeks of treatment according to the Chinese version of RSS-12 and RSI. After 12 weeks of treatment, the RFS scores significantly decreased compared to pretreatment levels （P<0.05）. After 12 weeks of antacid treatment, according to the Chinese version of RSS-12, 80% of patients in the observation group showed a good therapeutic response, compared to 64% in the control group; according to RSI, 90% of patients in the observation group showed a good therapeutic response, compared to 84% in the control group. There was no statistically significant difference in the treatment effect between the two groups after 12 weeks of treatment（P>0.05）. Conclusion:Vonoprazan fumarate can significantly improve the symptoms and signs of laryngopharyngeal reflux, and their treatment effect is not inferior to proton pump inhibitors. Compared with RSI, the Chinese version of RSS-12 can serve as a new screening tool for clinical diagnosis of LPRD in China.
Humans ; Sulfonamides/therapeutic use* ; Male ; Pyrroles/therapeutic use* ; Female ; Laryngopharyngeal Reflux/drug therapy* ; Treatment Outcome ; Middle Aged ; Esomeprazole/therapeutic use* ; Proton Pump Inhibitors/therapeutic use* ; Adult

Objective To investigate the cognition status of pediatric healthcare professionals about family's participation in their sick children's safety management, and to analyze its influencing factors, so as to provide references to promote family's participation effectively. Methods From July to August 2016, a questionnaire of healthcare professionals' perceptions about "patient for patient safety (PFPS)" was used to investigate 238 pediatric healthcare professionals who were from a class Ⅲ children's hospital about their overall cognition level and their attitudes towards current difficulties. The multiple regression analysis was used to analyze the factors affecting the overall perception level. Results The pediatric healthcare professionals scored (60.12±8.94) in their overall cognitive level, among which, (4.00±0.74) in knowledge level, (3.96±0.70) in their perception level about the favorable role of patients' family's participation, and (2.50±0.84) in their perception about the unfavorable role of participation. There was a statistically significant difference in the overall cognition scores of the pediatric healthcare professionals from different departments and whether or not they had received education or training about PFPS (P< 0.05). Pediatric healthcare professionals' perception about the existing main difficulties about PFPS were that "patients' expectations with treatment were too high", and "the media's report made the public mistrust and misunderstand the medical industry", as well as, "the public were unable to clearly understand the medical's uncertainty or risk". Conclusions The total cognitive level of pediatric healthcare professionals about family's participation in sick children's safety management needs enhancing. It is suggested that hospitals should strengthen the training plans about PFPS for pediatric healthcare professionals and create a patient safety culture atmosphere in various departments, in order to effectively promote family's participation. It is also suggested that the hospital should try their best to do a good job of health education for patients' family. Also the media and the public are expected to correctly understand the medical industry, and jointly help to build a harmonious relationship between doctors and patients.

Objective To analyze the biological activity of bioactive peptides in human breast milk and to find the polypeptides so as to investigate the preventive and therapeutic effects of breast milk-derived bioactive peptides on neonatal necrotizing enterocolitis(NEC).Methods Six mothers who gave birth to preterm neonates were enrolled in this study and 5 mL of their breast milk secreted within 2-5 postnatal days were collected for 6 times and blended subsequently.Bioactive peptides from maternal milk of the preterm infants were separated by ultrafiltration and analyzed by using tandem mass spectrometry.Polypeptides possibly with biological function were screened out by using bioinformatics software and the protein function cluster online analysis software was used to predict the polypeptides associated with infection according to the biological function of their precursor proteins.The ATCC25922,an Escherichia coli strain commonly associated with infection in NEC and drug solution (sulbactarr/cefoperazone) were used to conduct the drug susceptibility testing and bactericidal kinetics testing,so as to verify the antibacterial effects of bioactive peptides in the breast milk.Results Four thousand three hundred and eleven peptides contained in breast milk were identified successfully,of which 1 370 were non-differential peptides,and 188 peptides possibly with biological activity and 11 peptides were associated with infection.The peptide compound in the breast milk had antimicrobial activity and bactericidal power against Escherichia coli.Conclusions The active peptide compounds in the breast milk have antimicrobial activity,which play an important role in the prevention of NEC.Finding the true antimicrobial peptides with in vivo and in vitro biological activity by using antimicrobial spectrum test is expected.